Lilly partners with Innovent to develop cancer therapies
Eli Lilly & Co. penned an agreement with Innovent Biologics Inc. to develop at least three new cancer drugs in China over the next ten years.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com